Recursion to buy AI-enabled drug discovery startups Cyclica, Valence

Recursion agreed to buy Toronto-based Cyclica for $40 million and Montreal-based Valence for $47.5 million.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this